The Treatment of Possible Severe Infection in Infants: An Open Randomized Safety Trial of Parenteral Benzylpenicillin and Gentamicin Versus Ceftriaxone in Infants
Background:
The World Health Organization recommends benzylpenicillin and gentamicin as antimicrobial treatment for infants with sepsis in low-income settings, and ceftriaxone or cefotaxime as an alternative. In a meta-analysis from 13 low-income settings, Staphylococcus aureus, Klebsiella spp. and Escherichia coli accounted for 55% of infants with sepsis. In a review of bacterial meningitis, resistance to third generation cephalosporins was>50% of all isolates, and 44% of Gram-negative isolates were gentamicin resistant. However, ceftriaxone may cause neonatal jaundice, and gentamicin may cause deafness. Therefore, we compared parenteral benzylpenicillin plus gentamicin with ceftriaxone as first-line treatment, assessing outcome and adverse events.
Methods:
This was an open randomized trial carried out in the Queen Elizabeth Central Hospital, Blantyre, Malawi, from 2010 to 2013. Infants
Source: The Pediatric Infectious Disease Journal - Category: Infectious Diseases Tags: Maternal-Neonatal Reports Source Type: research
More News: Audiology | Ceftriaxone | Deafness | Gastroenteritis | Hospitals | Infectious Diseases | International Medicine & Public Health | Jaundice | Malawi Health | Men | Meningitis | Pediatrics | Perinatology & Neonatology | Rocephin | Staphylococcus Aureus | WHO